You are here

Article Text

Article menu
Download PDFPDF
Drug therapy
Original research
Gelatin tannate for acute diarrhoea and gastroenteritis in children: a systematic review and meta-analysis
  1. Ivan D Florez1,2,
  2. Javier M Sierra2,
  3. Laura F Niño-Serna2,3
  1. 1 Department of Health Research Methods Evidence and Impact, McMaster University, Hamilton, Ontario, Canada
  2. 2 Department of Pediatrics, Universidad de Antioquia, Medellin, Colombia
  3. 3 Department of Pediatrics, Hospital Pablo Tobon Uribe, Medellin, Antioquia, Colombia
  1. Correspondence to Dr Ivan D Florez, Health Research Methods Evidence and Impact, McMaster University, Hamilton, ON L8V 1 C3, Canada; ivan.florez{at}udea.edu.co

Abstract

Objective To determine the effectiveness and safety of gelatin tannate (GT) for reducing the duration of the acute diarrhoea and gastroenteritis (ADG) in children.

Design Systematic review and meta-analysis.

Data sources MEDLINE, Embase, CINAHL, Cochrane Central Register of Controlled Trials, LILACS and grey literature, published from inception to October 2018. No language restrictions.

Eligibility criteria for selecting studies Randomised controlled trials in children with ADG, comparing GT with placebo.

Results Of 797 titles identified, we included three studies (276 children). We performed a random effects model meta-analysis for the main outcome (diarrhoea duration). We did not find significant differences between GT and placebo for diarrhoea duration (mean difference (MD)=−15.85 hours; 95% CI −42.24 to 14.82, I2=92%; three studies), stool frequency at day 2 (MD=0.11 stools/day; 95% CI −0.39 to 0.62: I2=26%; two studies), diarrhoea at day 3 (risk ratio [RR]=0.46; 95% CI 0.06 to 3.47: I2=73%; two studies), vomiting (RR=1.31; 95% CI 0.95 to 1.80: I2=0%; two studies) or adverse events (RR=0.86; 95% CI 0.27 to 2.66: I2=0%; two studies). Most common adverse events included abdominal pain and nausea.

Conclusion The effect of GT was no different to placebo for mean diarrhoea duration (low certainty on the evidence) and stool frequency at day 2 (high certainty) and for the presence of diarrhoea at day 3 (very low certainty) of vomiting (moderate certainty) and of adverse events (low certainty).

PROSPERO registration number CRD42018087902.

  • diarrhoea
  • gastroenteritis
  • children
  • gelatin
  • tannate
  • meta-analysis
  • systematic review

https://doi.org/10.1136/archdischild-2018-316385

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Contributors Conceptualised and designed the study: IDF; selected the articles, extracted the data and assessed the quality of the evidence: all authors; analysed and interpreted the data: all authors; manuscript drafting: IDF.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; externally peer reviewed.

    • Data sharing statement All relevant data are within the paper and its supporting information files.

    • Patient consent for publication Not required.

    Linked Articles